In such an experimental setting, where [MNA + ]/[MNAH TOT ] is constant but the Nernstian term [MNA + ]/[MNAH] is changing, the theoretical curve of the electrode potential versus pH is given by the following function, as [MNAH] can be expressed from equation (9): where K is the protonation constant of MNAH
Legitimate Research Directions: Some peptides DO have potential and are being properly studied: Thymosin Alpha-1: Immune support (approved in 35+ countries, trials in US) BPC-157: IF proper human trials ever happen LL-37: Antimicrobial applications Others: Many peptides have theoretical promise But ONLY if studied properly: Randomized controlled trials Safety studies FDA approval process Medical supervision The Problem: Most "wellness peptides" will NEVER go through this process because: They can't be patented (no profit incentive) Companies would rather sell in gray market Proper trials cost $100M+ If trials show they DON'T work, the market disappears So we're stuck in limbo: promising animal data, zero human data, aggressive marketing
Neuroendocrinology Letters
While the formation of 5-(3,4-dihydroxyphenyl)--valerolactone from (+)-catechin by intestinal bacteria has already been described by Das ( Eggerthelia lenta and Adlercreutzia equolifaciens species, followed by activities of Flavonifractor plautii strains ( 2 , with monomers being linked via a single interflavan bond, are more readily cleaved compared to A-type procyanidins with two interflavan bonds ( After intake of Pycnogenol , the microbial metabolites 5-(3,4-dihydroxyphenyl)--valerolactone (previously also named -(3,4-dihydroxyphenyl)--valerolactone or M1) and 5-(3- methoxy-,4-hydroxyphenyl)--valerolactone (previously also called -(3- methoxy-,4-hydroxyphenyl)--valerolactone or M2) were identified in urine samples of a volunteer as phase II conjugates (
